WO2014102741A3 - Pharmaceutical dosage form - Google Patents
Pharmaceutical dosage form Download PDFInfo
- Publication number
- WO2014102741A3 WO2014102741A3 PCT/IB2013/061366 IB2013061366W WO2014102741A3 WO 2014102741 A3 WO2014102741 A3 WO 2014102741A3 IB 2013061366 W IB2013061366 W IB 2013061366W WO 2014102741 A3 WO2014102741 A3 WO 2014102741A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage form
- pharmaceutical dosage
- api
- shell
- swellable polymer
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 3
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 4
- 239000011159 matrix material Substances 0.000 abstract 3
- 229920000642 polymer Polymers 0.000 abstract 3
- 238000006073 displacement reaction Methods 0.000 abstract 1
- 230000008961 swelling Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nanotechnology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a pharmaceutical dosage form for delivery of, at a target site in a human or animal body, an active pharmaceutical ingredient (API), said pharmaceutical dosage form comprising a shell defining therein an outlet; a polymeric matrix having at least one API, the polymeric matrix received within the shell; and a swellable polymer body located within the shell, wherein the swellable polymer body is pH responsive, such that in use, exposure of the body to a medium of increasing pH causes an increase in swelling and an increase in volume of the swellable polymer body, which in turn, facilitates displacement of the matrix through the outlet toward the target site for delivery of the API.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ZA2012/07430 | 2012-12-28 | ||
ZA201207430 | 2012-12-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014102741A2 WO2014102741A2 (en) | 2014-07-03 |
WO2014102741A3 true WO2014102741A3 (en) | 2014-12-04 |
Family
ID=50070628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2013/061366 WO2014102741A2 (en) | 2012-12-28 | 2013-12-27 | Pharmaceutical dosage form |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2014102741A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3316873B1 (en) * | 2015-06-30 | 2021-04-28 | Entrega Inc. | Device for oral delivery of active agents |
CN106265530B (en) * | 2016-08-19 | 2018-11-02 | 浙江汇能生物股份有限公司 | A kind of Mercaptamine pre-mixing agent and preparation method thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4904474A (en) * | 1988-01-25 | 1990-02-27 | Alza Corporation | Delivery of drug to colon by oral disage form |
US4959218A (en) * | 1988-03-25 | 1990-09-25 | Alza Corporation | Method for delivering somatotropin to an animal |
US6004582A (en) * | 1997-05-30 | 1999-12-21 | Laboratorios Phoenix U.S.A, Inc. | Multi-layered osmotic device |
US6524305B1 (en) * | 1997-07-25 | 2003-02-25 | Alza Corporation | Osmotic delivery system flow modulator apparatus and method |
WO2004010981A1 (en) * | 2002-07-29 | 2004-02-05 | Alza Corporation | Methods and dosage forms for controlled delivery of paliperidone |
WO2007044234A1 (en) * | 2005-10-07 | 2007-04-19 | Alza Corporation | Osmotic dosage form with controlled release and fast release aspects |
WO2007140416A2 (en) * | 2006-05-30 | 2007-12-06 | Intarcia Therapeutics, Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATA7997A (en) | 1997-01-21 | 1998-03-15 | Bernkop Schnuerch Andreas | METHOD FOR PRODUCING CHITOSAN ETHYLENE DIAMINE TETRAACETATE CONJUGATES |
US8088734B2 (en) | 2003-01-21 | 2012-01-03 | Unigene Laboratories Inc. | Oral delivery of peptides |
US8348930B2 (en) | 2005-07-01 | 2013-01-08 | Microlin, Llc | Fluid delivery device with a diffusion membrane and electrochemical pump |
US8377863B2 (en) | 2007-05-29 | 2013-02-19 | Unigene Laboratories Inc. | Peptide pharmaceutical for oral delivery |
-
2013
- 2013-12-27 WO PCT/IB2013/061366 patent/WO2014102741A2/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4904474A (en) * | 1988-01-25 | 1990-02-27 | Alza Corporation | Delivery of drug to colon by oral disage form |
US4959218A (en) * | 1988-03-25 | 1990-09-25 | Alza Corporation | Method for delivering somatotropin to an animal |
US6004582A (en) * | 1997-05-30 | 1999-12-21 | Laboratorios Phoenix U.S.A, Inc. | Multi-layered osmotic device |
US6524305B1 (en) * | 1997-07-25 | 2003-02-25 | Alza Corporation | Osmotic delivery system flow modulator apparatus and method |
WO2004010981A1 (en) * | 2002-07-29 | 2004-02-05 | Alza Corporation | Methods and dosage forms for controlled delivery of paliperidone |
WO2007044234A1 (en) * | 2005-10-07 | 2007-04-19 | Alza Corporation | Osmotic dosage form with controlled release and fast release aspects |
WO2007140416A2 (en) * | 2006-05-30 | 2007-12-06 | Intarcia Therapeutics, Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
Non-Patent Citations (1)
Title |
---|
MALATERRE V ET AL: "Oral osmotically driven systems: 30 years of development and clinical use", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 73, no. 3, 1 November 2009 (2009-11-01), pages 311 - 323, XP026736254, ISSN: 0939-6411, [retrieved on 20090712], DOI: 10.1016/J.EJPB.2009.07.002 * |
Also Published As
Publication number | Publication date |
---|---|
WO2014102741A2 (en) | 2014-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ704011A (en) | Abuse deterrent pharmaceutical compositions for controlled release | |
EA201401139A1 (en) | SUSTAINABLE TO DESTRUCTION AND DOSE RELEASE PHARMACEUTICAL DRUG FORM | |
CL2013001497A1 (en) | Method for producing a pharmaceutical preparation containing a proton pump inhibitor and an aine in the form of spherical granules; pharmaceutical preparation; and its use for the treatment of pain and inflammation in rheumatism, bruises, sprains and osteoarthritis. | |
BRPI0719060A2 (en) | COMPOUND, PRODUCT, PHARMACEUTICAL AGENT, METHODS TO INHIBIT AN ANGIOTENSIN II RECEIVER AND / OR ACTIVATE A PEROXISOMAL ACTIVATED RECEIVER, AND TO PREVENT OR TREAT DISEASE OR CONDITION, AND, USE OF A COMPOUND | |
WO2016004048A3 (en) | Targeted conjugates and particles and formulations thereof | |
WO2012109022A3 (en) | Medical fluid delivery device programming | |
WO2008128740A8 (en) | Titration of tapentadol | |
WO2010035273A3 (en) | Novel gastroretentive delivery system | |
BRPI0816887A2 (en) | Drug delivery system, contraceptive methods, to concurrently provide contraception and treat or prevent a sexually transmitted disease, and to manufacture the three-layer drug delivery system, and use of the drug delivery system. | |
EP4233978A3 (en) | Oral delivery of active drug substances | |
WO2010139654A3 (en) | Orally disintegrating dosage forms containing taste-masked active ingredients | |
WO2012091748A3 (en) | Therapeutic agent reservoir delivery system | |
NZ608239A (en) | Aqueous drug delivery system comprising off - flavor masking agent | |
EA201690967A1 (en) | EYE DEVICE | |
IT1395128B1 (en) | DEVICE / SYSTEM FOR MIXING LIQUIDS, DRUGS AND SOLUTIONS BEFORE ADMINISTRATION INSIDE THE HUMAN BODY | |
BRPI0819115A2 (en) | Liquid aqueous formulation, nasal drug dispensing device or dosage cartridge, and use of solubilizing agent. | |
WO2011067667A3 (en) | Fexofenadine microcapsules and compositions containing them | |
MX344846B (en) | Combination of active loaded granules with additional actives. | |
MX2017003561A (en) | Compositions and methods for cannabinoid coatings for use in drug delivery. | |
MX2012013021A (en) | Alcohol-resistant formulations. | |
MX2017000041A (en) | Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides. | |
TR201010683A1 (en) | Vildagliptin formulations. | |
WO2016081835A3 (en) | Targeted structure-specific particulate delivery systems | |
WO2014102741A3 (en) | Pharmaceutical dosage form | |
WO2012172433A3 (en) | A sustained -release composition containing a melanocortin receptor ligand as the active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13828884 Country of ref document: EP Kind code of ref document: A2 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
122 | Ep: pct application non-entry in european phase |
Ref document number: 13828884 Country of ref document: EP Kind code of ref document: A2 |